Determination of oxidative stress and activities of antioxidant enzymes in guinea pigs treated with haloperidol

Experimental and Therapeutic Medicine

Volumn 5, Issue 2, 2013, Pages 479-484

  Gumulec, Jaromir ^a   Raudenska, Martina ^a   Hlavna, Marian ^a   Stracina, Tibor ^a   Sztalmachova, Marketa ^a,b   Tanhauserova, Veronika ^a   Pacal, Lukas ^a   Ruttkay Nedecky, Branislav ^b,c   Sochor, Jiri ^b,c   Zitka, Ondrej ^b,c,d   Babula, Petr ^d   Adam, Vojtech ^b,c   Kizek, Rene ^b,c   Novakova, Marie ^a,e   Masarik, Michal ^a,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^d UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^e BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

Author keywords

Glutathione reductase; Glutathione S transferase; Guinea pig; Haloperidol; Oxidative stress; Superoxide dismutase

Indexed keywords

GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HALOPERIDOL; PLACEBO; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; NONHUMAN; OXIDATIVE STRESS;

EID: 84871354255     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.822     Document Type: Article

References (28)

1. Janssen PA, Soudijn W, van Wijngaarden I and Dresse A: Pimozide, a chemically novel highly potent and orally long-acting neuroleptic drug. 3. Regional distribution of pimozide and of haloperidol in dog brain. Arzneimittelforschung 18: 282-287, 1968.
2. Ikemura M, Nakagawa Y, Shinone K, Inoue H and Nata M: The blood concentration and organ distribution of haloperidol at therapeutic and toxic doses in severe fatty liver disease. Leg Med (Tokyo) 14: 147-153, 2012.
3. Maxa JL, Taleghani AM, Ogu CC and Tanzi M: Possible toxic encephalopathy following high-dose intravenous haloperidol. Ann Pharmacother 31: 736-737, 1997.
4. Tsujimoto A, Tsujimoto G, Ishizaki T, Nakazawa S and IchihashiY: Toxic haloperidol reactions with observation of serum haloperidol concentration in two children. Dev Pharmacol Ther 4: 12-17, 1982.
5. Engel N and Mahlknecht U: Aging and anti-aging: Unexpected side effects of everyday medication through sirtuin1 modulation. Int J Mol Med 21: 223-232, 2008.
6. Huang QY, Li XF and Liu SP: E-cadherin and caveolin-1 alterations in the heart of rats having undergone chlorpromazine-induced toxicity. Mol Med Rep 5: 705-709, 2012.
7. Breier A, Schreiber JL, Dyer J and Pickar D: National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 48: 239-246, 1991.
8. Baldessarini RJ, Cohen BM and Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79-91, 1988.
9. Levenson JL: Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145, 1985.
10. Gorrod JW and Fang J: On the metabolism of haloperidol. Xenobiotica 23: 495-508, 1993.
11. Wright AM, Bempong J, Kirby ML, Barlow RL and BloomquistJR: Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788: 215-222, 1998.
12. Forsman A and Larsson M: Metabolism of haloperidol. Curr Ther Res Clin Exp 24: 567-568, 1978.
13. Fang J, Baker GB, Silverstone PH and Coutts RT: Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17: 227-233, 1997.
14. Eyles DW, McGrath JJ and Pond SM: Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) 125: 214-219, 1996.
15. Korpi ER, Costakos DT and Wyatt RJ: Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration. Acta Pharmacol Toxicol (Copenh) 56: 94-98, 1985.
16. Burkhardt C, Kelly JP, Lim YH, Filley CM and ParkerWD: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33: 512-517, 1993.
17. Shivakumar BR and Ravindranath V: Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265: 1137-1141, 1993.
18. Behl C, Lezoualc'h F, Widmann M, Rupprecht R and Holsboer F: Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res 717: 193-195, 1996.
19. Peet M, Laugharne J, Rangarajan N and Reynolds GP: Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 8: 151-153, 1993.
20. Pai BN, Janakiramaiah N, Gangadhar BN and Ravindranath V: Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 36: 489-491, 1994.
21. Sochor J, Ryvolova M, Krystofova O, etal: Fully automated spectrometric protocols for determination of antioxidant activity: advantages and disadvantages. Molecules 15: 8618-8640, 2010.
22. Lawler JM and Powers SK: Oxidative stress, antioxidant status, and the contracting diaphragm. Can J Appl Physiol 23: 23-55, 1998.
23. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L and Sindhu RK: Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63: 179-185, 2003.
24. Salinas AE and Wong MG: Glutathione S-transferases-a review. Curr Med Chem 6: 279-309, 1999.
25. Tan KL and Board PG: Purification and characterization of a recombinant human Theta-class glutathione transferase (GSTT2-2). Biochem J 315: 727-732, 1996.
26. Hubatsch I, Ridderström M and Mannervik B: Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J 330: 175-179, 1998.
27. Adler V, Yin ZM, Fuchs SY, etal: Regulation of JNK signaling by GSTp. EMBO J 18: 1321-1334, 1999.
28. Seeman PM and Bialy HS: The surface activity of tranquilizers. Biochem Pharmacol 12: 1181-1191, 1963.